Company Encyclopedia
View More
name
Immunic
IMUX.US
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc.
1.946 T
IMUX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immunic Inc. CEO to Join Evercore ISI Healthcare Conference Fireside Chat

    Immunic Inc.'s CEO, Daniel Vitt, Ph.D., will join the 8th Annual Evercore ISI Healthcare Conference for a fireside chat on December 4, 2025, at 9:35 am ET in Coral Gables, Florida. The event will be webcast on Immunic's website. This news was generated by Public Technologies using AI and is based on original content from PR Newswire.

    Reuters·
    US
    IMUX
    +5.89%
    Reuters·
    US
    IMUX
    +5.89%

    HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00

    HC Wainwright lowered Immunic's (NASDAQ:IMUX) target price from $10.00 to $8.00, maintaining a "buy" rating. Other analysts also adjusted their ratings, with some setting lower targets and others issuing "buy" ratings. Immunic's stock performance and institutional investor activities were highlighted. The company focuses on developing treatments for chronic inflammatory and autoimmune diseases. Recent earnings showed a slight beat on EPS estimates. The stock has a consensus rating of "Moderate Buy" with a target price of $7.40.

    Market Beat·
    US
    IMUX
    +5.89%
    Market Beat·
    US
    IMUX
    +5.89%

    H.C. Wainwright Remains a Buy on Immunic (IMUX)

    H.C. Wainwright's Matthew Caufield reiterated a Buy rating on Immunic (IMUX) with a price target of $8.00. Caufield, a 5-star analyst with a 16.9% average return, focuses on the Healthcare sector. Immunic has a Strong Buy consensus with a $4.25 price target consensus.

    Tip Ranks·
    US
    IMUX
    +5.89%
    Tip Ranks·
    US
    IMUX
    +5.89%

    Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path

    William Blair analyst Myles Minter reiterates a Buy rating for Immunic (IMUX) due to Vidofludimus calcium's efficacy and safety, strategic financial path, and patent protection until 2041. Despite financial challenges, funding is secured for trials in relapsing MS, with positive results expected by 2026. Minter, a 5-star analyst, highlights vido's competitive edge over existing treatments and its unique mechanism. Roth MKM also initiated coverage with a Buy rating and a $3.00 price target.

    Tip Ranks·
    US
    IMUX
    +5.89%
    Tip Ranks·
    US
    IMUX
    +5.89%

    Immunic | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    IMUX
    +5.89%
    LB filings·
    US
    IMUX
    +5.89%
    © 2025 Longbridge｜Disclaimer